Patent Assignment
Reel/Frame 073705/0109
Assignment of Assignor's Interest
Recorded: 2025-10-30
Pages: 11
Assignor
CELULARITY INC.
Executed: 2025-08-14
Assignee
CELENIV PTE. LTD.
3, LIM TECK KIM ROAD, #09-02, GENTING CENTRE, SINGAPORE, 088934, SINGAPORE
Covered Properties
(83)
Umbilical Cord Biomaterial for Medical Use
Expansion of Natural Killer Cells and ILC3 Cells with Novel Aromatic Compounds
Application:
17/309,449 →
Publication:
US US20230028680A1
Methods of Generating Natural Killer Cells
Natural Killer Cells from Placenta
Natural Killer Cells and ILC3 Cells and Uses Thereof
Application:
18/056,088 →
Publication:
US US20230142803A1
Methods of Treating Acute Myeloid Leukemia and Multiple Myeloma Using Natural Killer Cells
Enhanced Placental Stem Cells and Uses Thereof
Enhanced Placental Stem Cells and Uses Thereof
Enhanced Placental Stem Cells and Uses Thereof
Application:
18/048,291 →
Publication:
US US20230081199A1
Treatment of Inflammatory Diseases Using Placental Stem Cells
Treatment of Psoriasis Using Placental Stem Cells
Treatment of Inflammatory Diseases Using Placental Stem Cells
Treatment of Inflammatory Diseases Using Placental Stem Cells
Methods and Compositions for Treatment of Bone Defects with Placental Cell Populations
Methods and Compositions for Treatment of Bone Defects with Placental Cell Populations
Methods and Compositions for Treatment of Bone Defects with Placental Cell Populations
Tumor Suppression Using Placental Stem Cells
Treatment of Stroke Using Isolated Placental Cells
Cell Composition and Methods of Making the Same
CD34+,CD45- Placental Stem Cell-Enriched Cell Populations
Angiogenesis Using Placental Stem Cells
Treatment of Sarcoidosis Using Placental Stem Cells
Enhancement of Placental Stem Cell Potency Using Modulatory Rna Molecules
Treatment of Amyotrophic Lateral Sclerosis Using Placental Stem Cells
Treatment of Pain Using Placental Stem Cells
Treatment of Pain Using Placental Stem Cells
Angiogenesis Using Stimulated Placental Stem Cells
Application:
17/143,866 →
Publication:
US US20210230537A1
Immunomodulation Using Placental Stem Cells
Immunomodulation Using Placental Stem Cells
Immunomodulation Using Placental Stem Cells
Devices and Methods for Thawing Biological Material
Application:
17/302,353 →
Publication:
US US20210253327A1
Devices and Methods for Thawing Biological Material
Application:
16/011,599 →
Publication:
US US20190152676A1
Methods for Quantifying Particulates in Cell Culture
Use of Placental Stem Cells in Treatment of Acute Kidney Injury
Treatment of Bone-Related Cancers Using Placental Stem Cells
Placental Stem Cell Populations
Placental Stem Cell Populations
Placental Stem Cell Populations
Placental Stem Cell Populations
Placental Stem Cell Populations
Placenta-Derived Adherent Cell Exosomes and Uses Thereof
Patent:
11,173,182 →
Application:
16/740,054 →
Composition for Collecting and Preserving Placental Stem Cells and Methods of Using the Composition
Composition for Collecting and Preserving Placental Stem Cells and Methods of Using the Composition
Placenta-Derived Allogeneic Car-T Cells and Uses Thereof
Application:
17/309,451 →
Publication:
US US20220118014A1
Populations of Natural Killer Cells Comprising a CD38 Chimeric Antigen Receptor
Application:
17/630,079 →
Publication:
US US20220273716A1
Placenta Derived Adherent Cells for Improved Xenoplantation
Application:
17/439,671 →
Publication:
US US20220160787A1
Populations of Natural Killer Cells for Treating Cancers
Application:
17/619,242 →
Publication:
US US20220265712A1
Exosomes for Disease Treatment
Application:
17/596,827 →
Publication:
US US20230181649A1
Placenta-Derived Allogeneic Car-T Cells and Uses Thereof
Application:
17/830,865 →
Publication:
US US20250092363A1
Placenta-Derived Adherent (Pda) Stem Cell for the Treatment of Adults with Sars-Cov-2 Related Acute Respiratory Failure and Ards (Covid-19)
Application:
17/998,199 →
Publication:
US US20230210909A1
Cleavage Resistant CD16 Constructs and Uses Thereof
Application:
18/728,298 →
Publication:
US US20250295776A1
Multi-Layer Amniotic Tissue Grafts and Uses Thereof
Application:
18/555,412 →
Publication:
US US20240245830A1
Placenta-Dervied Nk Cells as a Senol Ytic for Therapeutic and Other Uses
Application:
18/293,243 →
Publication:
US US20250276063A1
Compositions and Methods for Treating Cancer
Application:
19/129,085 →
Publication:
US US20260183328A1
Dermal Rejuvenation Composition Comprising Placenta Derived Biomaterial and Uses Thereof
Application:
19/145,935 →
Publication:
US US20260207677A1
Placental Extracellular Matrices for Ocular Delivery of Ophthalmic Therapeutic Agents
Application:
19/153,403 →
Human Placental Derived Natural Killer Cells with High Affinity and Cleavage Resistant CD16 and Secreted IL-15, and uses thereof
Application:
18/921,811 →
Publication:
US US20260144871A1
Method for Modulating Glucagon-Like Peptide 1 (Glp-1) Agonist Induced Muscle Loss
Application:
19/094,351 →
Publication:
US US20260000712A1
Method for Modulating Glucagon-Like Peptide 1 (Glp-1) Agonist Induced Muscle Loss
Application:
63/571,116 →
Placental Tissue Compositions
Methods for Collecting and Using Placenta Cord Blood Stem Cells
Methods for Collecting and Using Placenta Cord Blood Stem Cells
Human Placental Collagen Compositions and Methods of Making and Using the Same
Human Placental Collagen Compositions, and Methods of Making and Using the Same
Human Placental Collagen Compositions, and Methods of Making and Using the Same
Human Placental Collagen Compositions, and Methods of Making and Using the Same
Human Placental Collagen Compositions, and Methods of Making and Using the Same
Treatment of Leg Ulcers Using Placenta Derived Collagen Biofabric
Tumor Suppression Using Human Placental Perfusate and Human Placenta-Derived Intermediate Natural Killer Cells
Method of Producing Erythrocytes
Patent:
9,200,253 →
Application:
12/187,337 →
Method of Producing Erythrocytes Without Feeder Cells
Method of Producing Erythrocytes Without Feeder Cells
Method of Producing Erythrocytes Without Feeder Cells
Genetically Modified Natural Killer Cells
Application:
17/645,004 →
Publication:
US US20220348875A1
Production of Oligodendrocytes from Placenta-Derived Stem Cells
Populations of Natural Killer Cells Comprising a Cleavage Resistant CD16
Application:
17/597,968 →
Publication:
US US20230355759A1
Compositions and Methods for Treating Cancer
PCT:
PCT/US2023/079857 ↗
A Dermal Rejuvenation Composition and Uses Thereof
PCT:
PCT/US2024/010457 ↗
Placental Extracellular Matrices for Ocular Delivery of Ophthalmic Therapeutic Agents
PCT:
PCT/US2024/013087 ↗
Bone Growth Composition
PCT:
PCT/US2024/021377 ↗
Decellularized Placental Extracellular Matrix and Uses Thereof
PCT:
PCT/US2024/039928 ↗
Decellularized Placenta Extracellular Matrix and Uses Thereof
PCT:
PCT/US2024/061317 ↗
A Method of Treating Signs or Symptoms of the Aging Process
PCT:
PCT/US2025/013037 ↗
Related Assignments
(18)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Dec 7, 2007
From: LIU, QING; RENDON BARRAGAN, HENRY; MATCHAM, GEORGE
To: ANTHROGENESIS CORPORATION
Reel/Frame 020212/0572 →
Assignment of Assignor's Interest
Jun 17, 2008
From: PALUDAN, CASPER; EDINGER, JAMES W.; HARBACHEUSKI, RYHOR; MURRAY, ROSEANN
To: ANTHROGENESIS CORPORATION
Reel/Frame 021108/0635 →
Assignment of Assignor's Interest
Jun 27, 2008
From: EDINGER, JAMES W.; HARIRI, ROBERT J.; WANG, JIA-LUN; YE, QIAN
To: ANTHROGENESIS CORPORATION
Reel/Frame 021166/0157 →
Assignment of Assignor's Interest
Feb 25, 2009
From: EDINGER, JAMES W.; HARIRI, ROBERT J.; WANG, JIA-LUN; YE, QIAN
To: ANTHROGENESIS CORPORATION
Reel/Frame 022313/0313 →
Assignment of Assignor's Interest
Oct 19, 2009
From: ZEITLIN, ANDY; PAL, AJAI
To: ANTHROGENESIS CORPORATION
Reel/Frame 023393/0049 →
Assignment of Assignor's Interest
Dec 14, 2011
From: HARIRI, ROBERT J.; HEIDARAN, MOHAMMAD A.; JASKO, STEPHEN; KANG, LIN
To: ANTHROGENESIS CORPORATION
Reel/Frame 027386/0326 →
Assignment of Assignor's Interest
May 25, 2012
From: EDINGER, JAMES; YE, QIAN; WANG, JIA-LUN; HARIRI, ROBERT J.
To: ANTHROGENESIS CORPORATION
Reel/Frame 028272/0851 →
Assignment of Assignor's Interest
Nov 4, 2015
From: EDINGER, JAMES W.; HARIRI, ROBERT J.; WANG, JIA-LUN; YE, QIAN
To: ANTHROGENESIS CORPORATION
Reel/Frame 036957/0993 →
Assignment of Assignor's Interest
Aug 11, 2016
From: ANTHROGENESIS CORPORATION, A NEW JERSEY CORPORATION, D/B/A CELGENE CELLULAR THERAPEUTICS
To: HLI CELLULAR THERAPEUTICS, LLC, A DELAWARE LIMITED LIABILITY COMPANY
Reel/Frame 039411/0443 →
Merger
Nov 8, 2017
From: ANTHROGENESIS CORPORATION
To: CLARITY ACQUISITION II LLC
Reel/Frame 044413/0680 →
Change of Name
Nov 9, 2017
From: HLI CELLULAR THERAPEUTICS, LLC
To: CELULARITY BIOSOURCING, LLC
Reel/Frame 044707/0351 →
Assignment of Assignor's Interest
Nov 9, 2017
From: CLARITY ACQUISITION II LLC
To: CELULARITY, INC.
Reel/Frame 044780/0261 →
Assignment of Assignor's Interest
Nov 11, 2017
From: CELULARITY BIOSOURCING, LLC
To: CELULARITY, INC.
Reel/Frame 044098/0717 →
Assignment of Assignor's Interest
Oct 20, 2022
From: ABBOT, STEWART; KARASIEWICZ-MENDEZ, KATHY; ZHANG, XIAOKUI; HARIRI, ROBERT J.
To: CELULARITY INC.
Reel/Frame 061479/0032 →
Assignment of Assignor's Interest
Feb 1, 2023
From: HARIRI, ROBERT J.; ZHANG, XIAOKUI; KANG, LIN; VAN DER TOUW, WILLIAM
To: CELULARITY INC.
Reel/Frame 062561/0409 →
Corrective Assignment to Correct the Property Number 2 (Application No. with Typo) Previously Recorded at Reel: 061479 Frame: 0032. Assignor(S) Hereby Confirms the Assignment.
Feb 2, 2023
From: ABBOTT, STEWART; KARASIEWICZ-MENDEZ, KATHY; ZHANG, XIAOKUI; HARIRI, ROBERT J.
To: CELULARITY INC.
Reel/Frame 062971/0107 →
Assignment of Assignor's Interest
Feb 24, 2023
From: CLARITY ACQUSITION II LLC
To: CELULARITY INC.
Reel/Frame 062852/0750 →
Merger
Feb 24, 2023
From: ANTHROGENESIS CORPORATION
To: CLARITY ACQUISITION II LLC
Reel/Frame 062795/0601 →